GÖTTINGEN, Germany,
Oct. 13, 2021 /PRNewswire/ --
Karin Sartorius-Herbst and
LifeScience Holding SCSp ("LSH") have entered into option
agreements to acquire a total portion of approximately 56.7 percent
of the shares of inheritances ("Erbteile") of the Horst Sartorius
community of heirs ("Erbengemeinschaft") from other members of the
Sartorius family.
In total, the inheritances of the joint heirship comprise 50.09%
of the ordinary shares of Sartorius AG. Unaffected by the
above-described transaction, all shares of the joint heirship
continue to be subject to administration by the executor until
mid-2028. Lothar Kappich, who is also chairman of the supervisory
board of Sartorius AG, will continue to administer the executorship
("Testamentsvollstreckung") as executor of the will.
Karin Sartorius-Herbst is a
member of the Sartorius community of heirs since it has been
established in 1998. LSH is a consortium of long-term oriented
entrepreneurs and entrepreneurial families and is led by
Armira.
The agreement remains subject to common conditions and approvals
and is expected to close by the end of 2021. The parties involved
have agreed not to disclose any further details of the transaction.
The changed composition of the joint heirship has no impact on the
strategic direction and the management of Sartorius AG.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
About Karin
Sartorius-Herbst
Karin Sartorius-Herbst is the
eldest daughter of testator Horst Sartorius. Since his death in
1998 she is a member of the community of heirs and currently holds
a third of it.
About Armira
Armira is a Munich-based
holding group that invests in established, profitable and
fast-growing companies in Europe,
with a focus on family businesses and technology. With its unique
capital base of German and international entrepreneurs as well as
entrepreneurial families, Armira has the flexibility to invest
without a fixed term and to focus on the long-term development of
the companies.
About Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros. At the end of 2020, nearly 11,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe.
Follow Sartorius on Twitter and on LinkedIn.
Contact
Petra
Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686
petra.kirchhoff@sartorius.com
View original
content:https://www.prnewswire.com/news-releases/change-in-composition-of-sartorius-joint-heirship-301398861.html
SOURCE Sartorius AG